Parakkal Deepak, MD
Gastroenterology · Saint Louis, MONPI 1972811974
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $136,319 of the $204,727 with a category attached, or 66.6%. 22 manufacturers reported payments, led by Johnson & Johnson at 27.3% of the total. 2025 is the largest year on record at $121,668, more than ten times the $271 reported in 2019. Among gastroenterology clinicians in MO with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 189 payments — averaging $1083.21 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$56K
- Eli Lilly$25K
- E.r. Squibb & Sons, L.L.C.$24K
- Takeda Pharmaceuticals U.S.A., Inc.$19K
- AbbVie$16K
- Sobi, Inc$12K
- plus $52K from 16 others
Across 217 payments — averaging $8474.41 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Takeda Pharmaceuticals U.S.A., Inc.$532K
- Bristol Myers Squibb$432K
- Teva Pharmaceuticals USA, Inc.$245K
- E.r. Squibb & Sons, L.L.C.$152K
- Pfizer$138K
- AbbVie$99K
- plus $240K from 7 others
What the payments were for
- Consulting fees$136,31967%
- Speaking & faculty fees$49,68424%
- Travel & lodging$13,1396%
- Food & beverage$5,4453%
- Education$1400%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson | 45 | $55,796 |
| Eli Lilly | 8 | $24,524 |
| E.r. Squibb & Sons, L.L.C. | 5 | $24,418 |
| Takeda Pharmaceuticals U.S.A., Inc. | 10 | $18,995 |
| AbbVie(2 entities) | 44 | $16,460 |
| Sobi, Inc | 10 | $12,137 |
| Janssen Scientific Affairs, LLC | 9 | $11,805 |
| Hexal AG | 2 | $9,113 |
| Merck | 9 | $8,525 |
| Celltrion USA Inc. | 6 | $8,275 |
| Lilly USA, LLC | 2 | $4,950 |
| Boehringer Ingelheim | 1 | $2,600 |
| Genentech, Inc. | 1 | $2,415 |
| Boehringer Ingelheim International GmbH | 3 | $2,029 |
| Bristol Myers Squibb | 15 | $1,674 |
| Fresenius Kabi USA, LLC | 1 | $610 |
| Pfizer | 12 | $149 |
| Cordis US CORP. | 1 | $86 |
| Mindray DS USA, Inc. | 2 | $82 |
| Samsung HME America, Inc. | 1 | $50 |
| Shire North American Group Inc | 1 | $18 |
| Cumberland Pharmaceuticals, Inc. | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$204,727 in reported general payments places this provider in the 95th percentile of 374 gastroenterology providers in Missouri.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| StelaraUstekinumab | 219 | $6,052,126 |
| Skyrizi On-BodyRisankizumab-Rzaa | 52 | $1,092,723 |
| Humira(Cf) PenAdalimumab | 48 | $576,638 |
| RinvoqUpadacitinib | 47 | $402,184 |
| EntyvioVedolizumab | 20 | $175,949 |
| XeljanzTofacitinib Citrate | 13 | $73,984 |
| Mesalamine | 76 | $28,707 |
| Opium Tincture | 11 | $3,174 |
| Colestipol Hcl | 21 | $2,798 |
| Mesalamine ErMesalamine | 24 | $2,237 |
| Sulfasalazine | 35 | $1,800 |
| Azathioprine | 34 | $1,796 |
| LoperamideLoperamide Hcl | 25 | $1,409 |
| Diphenoxylate-AtropineDiphenoxylate Hcl/Atropine | 25 | $840 |
| MethotrexateMethotrexate Sodium | 28 | $606 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonStelara | $55,796 | $6,052,126219 claims |
| AbbVieRinvoq | $16,460 | $402,18447 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Entyvio | $18,995 | $175,94920 claims |
| PfizerXeljanz | $149 | $73,98413 claims |
| Fresenius Kabi USA, LLCSodium Chloride | $610 | $3113 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 374 gastroenterology providers in Missouri.
Other gastroenterology in Saint Louis
- Gregory SayukSaint Louis$1.1M
- Katie SchroederSaint Louis$730K
- David AlpersSaint Louis$616K
- Mauricio Lisker MelmanSaint Louis$179K
- Matthew CiorbaSaint Louis$156K
- Bruce BaconSaint Louis$138K
- Jeffrey CrippinSaint Louis$120K
- Vladimir KushnirSaint Louis$118K
- Kayci Huff-HardySaint Louis$116K
- Rajesh KeswaniSaint Louis$109K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.